Fig. 2. Evidence-based medication prescriptions

Slides:

Advertisements

Similar presentations

Cardiac Drugs in Heart Failure Patients Zoulikha Zair 28 th May 2013 N.B. some drugs overlap with treatment of hypertension….bonus revision wise!!!!

Advertisements

1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

ACUTE MYOCARDIAL INFARCTION Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Emergency Medical Services Hospital Departments:

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.

Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz RRT, MS, Administrative.

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

CHF Team Approach Peter Carson, MD Jacqueline Gannuscio, MSN, ACNP RN Washington DC.

PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

HEART FAILURE TEAM MEMBERSHIP DEPARTMENTS OF CARDIOLOGY, CARDIOVASCULAR SURGERY, MEDICINE, NURSING, QUALITY AND RESOURCE MANAGEMENT, THE CENTER FOR CLINICAL.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Fig ACCF/AHA Guideline for the management of heart failure

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Algorithm for guideline-directed medical therapy for patients with SIHD. Colors correspond to the class of recommendations in the ACCF/AHATable The.

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Myocarditis in Clinical Practice

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Diabetes Mellitus and Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? Sumeet Gupta, MPharm, PhD,

Joerg Herrmann, MD, Amir Lerman, MD, Nicole P

Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From.

Figure 1 Energy supply–demand matching in health and heart failure

Viper venom for diabetic nephropathy

Step Care Therapy for Hypertension in Diabetic Patients

Eugene Braunwald JCHF 2013;1:1-20

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Sexual Activity and Chronic Heart Failure

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Nat. Rev. Cardiol. doi: /nrcardio

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Volume 94, Issue 3, Pages (September 2018)

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Age-dependent care and long-term (20year) mortality of 14,434 myocardial infarction patients: Changes from 1985 to 2008 Sjoerd T. Nauta, Jaap W. Deckers,

Rami Doukky et al. JCHF 2016;4:24-35

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Volume 73, Issue 5, Pages (March 2008)

Absolute mortality difference Change in LVEF from baseline

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Propensity score-matching

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

β-Blocker Use for the Stages of Heart Failure

Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Robert J. DiDomenico, PharmD, Malek G. Massad, MD

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy Andrea M. Steely, MD, Peter W.

Presentation transcript:

Fig. 2. Evidence-based medication prescriptions Fig. 2. Evidence-based medication prescriptions. (A) Prescription rate of angiotensin converting enzyme inhibitors: angiotensin receptor blockers: beta-blockers and aldosterone antagonists for acute heart failure patients. (B) Prescription rate changes in evidence-based medication before and after interim analysis. LVEF: left ventricular ejection fraction, ACEIs: angiotensin converting enzyme inhibitor, ARBs: angiotensin receptor blockers, BBs: beta-blockers, AAs: aldosterone antagonist. Fig. 2. Evidence-based medication prescriptions. (A) Prescription rate of angiotensin converting enzyme inhibitors: angiotensin receptor blockers: beta-blockers and aldosterone antagonists for acute heart failure patients. (B) Prescription rate changes in evidence-based medication before and after interim analysis. LVEF: left ventricular ejection… Korean Circ J. 2017 May;47(3):341-353. https://doi.org/10.4070/kcj.2016.0419